Pangaea OncologyXMAD:PANG 63 Quick Ratio is 1.74 as of Dec. 2025, which is 36% above its 10-year median of 1.28. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Pangaea Oncology ranks better than 50.93% on this metric.
Pangaea Oncology has a quick ratio of 1.74. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pangaea Oncology's Quick Ratio or its related term are showing as below:
XMAD:PANG'
s Quick Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.28 Max: 4.8
Current: 1.74
During the past 13 years, Pangaea Oncology's highest Quick Ratio was 4.80. The lowest was 0.78. And the median was 1.28.
XMAD:PANG's Quick Ratio is ranked better than 50.93% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.715
vs XMAD:PANG: 1.74
Pangaea Oncology (XMAD:PANG) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Pangaea Oncology Quick Ratio Related Terms
Pangaea Oncology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Pangaea Oncology's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a Quick Ratio of 1.74 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pangaea Oncology and its competitors. This is 36% above median its historical median of 1.28. Over the past decade, Pangaea Oncology's Quick Ratio has ranged from 0.78 to 4.80. According to the industry distribution chart, Pangaea Oncology ranks #105 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 49.1%.
Is Pangaea Oncology's Quick Ratio too high?
Pangaea Oncology's current Quick Ratio of 1.74 is 36% above median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 4.80. The Medical Diagnostics & Research industry median Quick Ratio is 1.72. Pangaea Oncology's value of 1.74 is 1.5% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #105 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #105 out of 214 companies for Quick Ratio. This puts Pangaea Oncology in the upper half of its industry. The industry median Quick Ratio is 1.72. Pangaea Oncology's value of 1.74 is 1.5% above this benchmark. Historically, Pangaea Oncology's own Quick Ratio has ranged from 0.78 to 4.80 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 1.72, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.72, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Quick Ratio of 1.74 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Quick Ratio is 1.74, which is 36% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Quick Ratio is 1.74, which is 36% above median its 10-year median of 1.28 and 1.5% above the Medical Diagnostics & Research industry median of 1.72. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Quick Ratio is 1.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Quick Ratio: 1.74 (36% above median its 10-year median of 1.28)
GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
Industry Position: 1.5% above the Medical Diagnostics & Research median (#105 of 214)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
